Terms: = Prostate cancer AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2 AND Treatment
5 results:
1. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Takayama KI; Suzuki T; Tanaka T; Fujimura T; Takahashi S; Urano T; Ikeda K; Inoue S
Oncogene; 2018 Apr; 37(16):2165-2180. PubMed ID: 29379164
[TBL] [Abstract] [Full Text] [Related]
2. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
Ashikari D; Takayama K; Tanaka T; Suzuki Y; Obinata D; Fujimura T; Urano T; Takahashi S; Inoue S
Oncogene; 2017 Nov; 36(45):6272-6281. PubMed ID: 28692047
[TBL] [Abstract] [Full Text] [Related]
3. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract] [Full Text] [Related]
4. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells.
Kim DK; Yang JS; Maiti K; Hwang JI; Kim K; Seen D; Ahn Y; Lee C; Kang BC; Kwon HB; Cheon J; Seong JY
Cancer Res; 2009 Feb; 69(3):923-31. PubMed ID: 19176390
[TBL] [Abstract] [Full Text] [Related]
5. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract] [Full Text] [Related]
